The peer-reviewed Phase 2a survival data substantially exceed historical benchmarks and support the Phase 3 AURORA trial's registration potential. Monitor AURORA enrollment updates and interim data readouts for the next catalyst.
Price Chart
Executive Summary
Candel Therapeutics announced peer-reviewed publication of final Phase 2a data for aglatimagene besadenovec plus valacyclovir in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors, showing median overall survival of 24.5 months versus ~9.8-11.8 months for standard-of-care docetaxel. The data support the ongoing pivotal Phase 3 AURORA trial, which is enrolling globally across ~150 sites.
Key Facts
- Median overall survival of 24.5 months in evaluable population (n=46) with stage III/IV NSCLC after inadequate ICI response, vs. 9.8-11.8 months historical benchmark for docetaxel
- In patients with progressive disease on ICI (cohort 2, n=41), mOS was 21.5 months; 37% alive beyond 24 months
- Non-squamous NSCLC patients with progressive disease (n=33) showed mOS of 25.4 months; 14/15 survived beyond 24 months, 9/9 beyond 30 months
- 69% of evaluable patients with >1 lesion exhibited abscopal response (reduction of uninjected lesions)
- Grade 3 treatment-related adverse events in 13.7% of patients; no dose-limiting toxicities or unexpected safety signals
- Global Phase 3 AURORA trial enrolling patients across ~150 sites, evaluating aglatimagene + valacyclovir + continued pembrolizumab vs. docetaxel in metastatic stage IV non-squamous NSCLC
- Data published in Journal for ImmunoTherapy of Cancer, a leading peer-reviewed oncology journal
Financial Impact
No financial figures disclosed; clinical-stage company with no approved products or revenue
Risk Factors
- Phase 3 AURORA trial may fail to replicate Phase 2a results in a larger, randomized setting
- Aglatimagene is not yet approved by FDA or any regulatory authority; regulatory pathway and timeline uncertain
- Clinical-stage biotech with no revenue; reliance on capital markets for funding
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372862 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers